Edward Kaye is stepping down as CEO of Stoke Therapeutics, just weeks after securing a vital deal with Biogen on its late-stage Dravet syndrome candidate, zorevunersen.
The announcement of Kaye’s departure after seven years at the helm came as a surprise to investors on 18 March,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?